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ABSTRACT
The MDM2 promoter region contains several polymorphisms, some of which have 
been associated with MDM2 expression, cancer risk and age at cancer onset. del1518 
(rs3730485) is an indel polymorphism residing in the MDM2 promoter P1 and is in almost 
complete linkage disequilibrium with the MDM2 promoter P2 polymorphism SNP309T>G 
(rs2279744). Cancer risk assessments of del1518 have previously been conducted 
in relatively small Chinese populations only. In this study we assessed the genotype 
distribution of del1518 among healthy Caucasians, African Americans and Chinese, and we 
estimated the Odds Ratios (OR) for incident cancer of the breast, colon, lung and prostate 
(n=7,081) as compared to controls (n=3,749) in a large Caucasian (Norwegian) cohort.
We found the genotypes of the del1518 to vary significantly between healthy 
Caucasians, African-Americans and Chinese (p< 1×10-5). Further, we found a positive 
association of the del1518 del-allele with risk of colon cancer (dominant model: OR = 
1.15; 95 % CI = 1.01 – 1.31). Stratifying according to SNP309 status, this association 
remained among carriers of the SNP309TG genotype (OR = 1.21; 95 % CI = 1.01 – 1.46), 
but with no clear association among carriers of the SNP309TT genotype. In conclusion, 
our findings suggest del1518 to be associated with increased risk of colon cancer.
INTRODUCTION
The Mouse Double Minute 2 homolog (MDM2) 
is a major regulator of the tumor suppressor p53. The 
levels of MDM2 and p53 are tightly regulated, as they 
act in a negative feedback loop where p53 induces 
MDM2 transcription in response to genotoxic stress, 
whereas MDM2 binds, inhibits and directs p53 for 
proteasomal degradation by ubiquitinylation [1–4]. 
MDM2 hyperactivity through mechanisms such as gene 
amplification, increased transcription and enhanced 
translation is observed in many human cancers harboring 
wild-type TP53 [5–7], and MDM2 overexpression has 
been suggested to act as an alternative mechanism of p53 
inactivation, thus promoting tumor growth.
While multiple single nucleotide polymorphisms 
(SNPs) have been identified in MDM2 promoter regions, so 
far, only a few have been assessed with respect to potential 
biological functions. SNP309T>G; rs2279744, located in 
the MDM2 promoter P2, has been shown to increase MDM2 
expression by increasing the binding affinity between the 
promoter and the transcription factor Sp1 [8]. The same 
investigators found the SNP309G allele to be associated 
with early onset of several malignancies among individuals 
carrying TP53 germline mutations (Li-Fraumeni syndrome) 
and also lower age at diagnosis of estrogen receptor (ER) 
rich breast cancer among individuals with wild-type TP53 
[9, 8]. Subsequent findings, with respect to the influence of 
SNP309 status on age at cancer onset as well as cancer risk 
have, however, been conflicting [10–17].
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Recently, we reported a second MDM2 promoter P2 
polymorphism, SNP285G>C; rs117039649 [18]. SNP285 
is in complete linkage disequilibrium (LD) with SNP309; 
thus forming a distinct SNP285C/309G haplotype [18, 
19]. The SNP285C allele diminish Sp1 binding to the 
MDM2 promoter, and has been found to be associated with 
reduced risk for breast, ovarian and endometrial cancer 
[18, 20–22], but was not associated with prostate or lung 
cancer risk [20, 21, 23].
del1518 (rs3730485), is an insertion/deletion 
polymorphism of 40 bps in the MDM2 promoter P1 [24, 
25]. The del1518 del-allele has been shown to reduce 
transcription from the MDM2 P1 promoter in some cell 
lines [26] and LD analysis has shown that the del1518 
locus has a high LD with the SNP309 locus [24]. Some 
small studies have assessed the potential effects of the 
del1518-variant on cancer risk, and reported that the 
del1518 del allele may be associated with an increased 
risk for hepatocellular carcinoma [27] but to be unrelated 
to risk for several other cancer forms, including cancer of 
the lung [24], breast [25] ovary [28] or esophagus [29] in 
Chinese populations.
In the present case-control study we compared 
del1518 distribution across ethnic cohorts (Caucasians, 
African Americans and Han Chinese) and assessed the 
association of del1518 status with the risk for breast-, 
lung-, colon- and prostate cancer.
RESULTS
MDM2 del1518 was determined in 7,081 Norwegian 
patients diagnosed with incidental cancers of the breast, 
colon, prostate or lung as well as 3,749 age-matched 
healthy individuals. In addition, to assess potential ethnic 
differences in del1518 distribution, we analyzed a cohort 
of 300 healthy African-Americans, and performed data 
mining from previously published del1518 genotyping of 
Chinese individuals (including 2,594 Chinese samples) 
[24, 25, 27–29].
Distribution of del1518
Among the 3,749 healthy Caucasian (Norwegian) 
individuals, we found the MAF of del1518 to be 0.42 
and the genotype distribution to be in Hardy-Weinberg 
equilibrium (p = 0.5). Interestingly, this differed 
(p = 0.015) from the distribution observed in African 
Americans (MAF = 0.38). It also differed (p < 1x10-5) 
from the distribution previously reported in Chinese 
populations (MAF = 0.30) [24, 25, 27–29] (comparison 
of genotype distribution between all three populations, 
p < 1x10-5; Figure 1A).
Except for five individuals harboring the del1518 
del/del – SNP309TG genotype and two individuals 
harboring the del1518 ins/del – SNP309GG (in the 
Caucasian cohort), the del1518 del variant was restricted 
to individuals carrying the SNP309TT or SNP309TG 
genotype, and del1518 del/del homozygosity was only 
seen among individuals carrying the SNP309TT genotype 
(Table 1; Figure 1B). Thus, we observed a very strong 
linkage disequilibrium (LD) between the del1518 variant 
and SNP309 (D’=0.999 for the healthy controls and D’ = 
0.997 for the entire sample set, including cancer patients). 
This observation is in accordance with previous findings 
in a Chinese population [24].
MDM2 del1518 and cancer risk
In order to assess the potential impact of del1518-
status on cancer risk, we first performed in silico analyses 
of putative de novo transcription factor binding sites 
created by the deletion. Applying the prediction algorithm 
in the JASPAR database [30] with default settings (cut 
off threshold of 80%), we found the breakpoint of the 
del-variant, with flanking nucleotides, to generate new 
binding sites for RORA (RAR-Related Orphan Receptor 
A), MEF2A (Myocyte Enhancer Factor 2A) and MIZF 
(MBD2 (methyl-CpG-binding protein)-interacting zinc 
finger protein) (Figure 2).
To determine the potential correlation between 
MDM2 del1518 status and cancer risk, we analyzed the 
distribution of this variant in large sample sets of incident 
cases of four major cancer forms (1,717 breast, 1,532 
colon, 1,331 lung and 2,501 prostate cancer samples) 
drawn from the population-based Cohort of Norway 
(CONOR) [31] and compared the distribution to 3,749 
matched controls without any cancer from the same 
cohort. The genotype distributions and the results from 
calculations of Odds Ratios (OR) between patients and 
controls are summarized in Table 2.
In overall assessments applying a dominant model, 
the del1518 del allele was associated with an increased 
risk of colon cancer (OR = 1.15; 95 % CI = 1.01 – 1.31; 
Table 2, Figure 3, Supplementary Table S1). Notably, this 
association was more pronounced among patients with left 
sided colon cancer (dominant model: OR = 1.21; 95 % 
CI = 1.01 - 1.45), compared to patients with right sided 
tumors (dominant model: OR = 1.14; 95 % CI = 0.97 – 
1.33; Table 2, Figure 3, Supplementary Table S1). For 
the three other cancer forms, no statistically significant 
association between del1518 status and cancer risk was 
recorded (Table 2, Figure 3, Supplementary Table S1).
Potential interactions between MDM2 del1518 
status and MDM2 SNP309
In the samples investigated in this study we have 
previously reported the MDM2 SNP309GG/TG genotypes 
to be associated with reduced risk of lung cancer among 
women, but not associated with risk of breast-, colon- 
or prostate cancer [20]. Given that the del1518 del was 
strongly linked to the SNP309T allele, we further refined 
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Figure 1: Genotype distribution and haplotype-tree. A. Genotype distribution of MDM2 SNP del1518 among Caucasians, African 
Americans and Chinese (Chinese data extracted from previous publications [24, 25, 27–29]). B. Haplotype-tree based on the three MDM2 
SNPs; del1518 (rs3730485), SNP309 (rs2279744) and SNP285 (rs117039649). The tree and the frequencies given for each haplotype are 
based on 3,749 healthy controls in the CONOR cohort and 300 healthy African Americans.
Table 1: Distribution of MDM2 del1518 – SNP309 haplotypes (alleles)
Haplotype Healthy controls Breast cancer Colon cancer Lung cancer Prostate cancer
del1518 - 309 N % n % n % n % n %
ins – T 1561 20,82 675 19,66 646 21,08 572 21,49 1058 21,15
ins – G 2786 37,16 1296 37,74 1085 35,41 946 35,54 1854 3707
del – T 3150 42,01 1463 42,60 1331 43,44 1143 42,94 2087 41,72
del – G 1 0,01 0 0 2 0,007 1 0,04 3 0,06
Total 7498 100 3434 100 3064 100 2662 100 5002 100
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Figure 2: MDM2 promoter P1 del1518 break-point sequence context. Novel transcription factor binding sites generated by the 
MDM2 del1518 del allele, as predicted by the JASPAR database (indicated by horizontal lines under the sequence). The predicted binding 
scores are annotated in the brackets. * indicates binding sites located on the reverse strand.















Healthy Controls 1285 (34.3) 1777 (47.4) 687 (18.3) 1.00 - 1.00 -
 Women 636 (34.0) 877 (46.9) 359 (19.2) 1.00 - 1.00 -
 Men 649 (34.6) 900 (47.9) 328 (17.5) 1.00 - 1.00 -
Colon cancer 478 (31.2) 775 (50.6) 279 (18.2) 1.15 (1.01-1.31) 0.034 0.99 (0.85-1.16) 0.938
 Women 237 (30.4) 393 (50.5) 149 (19.1) 1.18 (0.98-1.41) 0.077 1.00 (0.81-1.23) 1.000
 Men 241 (32.0) 382 (50.7) 130 (17.3) 1.12 (0.94-1.35) 0.218 0.99 (0.79-1.23) 0.955
  Left side 190 (30.2) 331 (52.5) 109 (17.3) 1.21 (1.01-1.45) 0.045 0.93 (0.75-1.17) 0.577
  Right side 261 (31.5) 410 (49.5) 158 (19.1) 1.14 (0.97-1.33) 0.133 1.05 (0.87-1.27) 0.621
Lung cancer 447 (33.6) 624 (46.9) 260 (19.5) 1.03 (0.90-1.18) 0.662 1.08 (0.92-1.27) 0.346
 Women 155 (31.2) 247 (49.7) 95 (19.1) 1.14 (0.92-1.40) 0.261 1.00 (0.78-1.28) 1.000
 Men 292 (35.0) 377 (45.2) 165 (19.8) 0.98 (0.83-1.16) 0.827 1.17 (0.95-1.43) 0.161
Breast cancerc 581 (33.8) 809 (47.1) 327 (19.0) 1.01 (0.88-1.16) 0.944 0.99 (0.84-1.17) 0.932
Prostate cancerd 836 (33.4) 1240 (49.6) 425 (17.0) 1.05 (0.93-1.19) 0.439 1.02 (0.85-1.22) 0.853
adel/del + ins/del versus ins/ins
bdel/del versus ins/del + ins/ins
ccompared to female controls only
dcompared to male controls only
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our analyses by removing individuals harboring the 
SNP309GG genotype and assessed the effect of del1518 
separately in individuals harboring the SNP309TG or 
SNP309TT genotype. Among individuals carrying the 
SNP309TT genotype, no association was recorded in 
either analysis (Table 3A, Figure 4A). However, among 
individuals with the SNP309TG genotype, the del1518 del 
allele was associated with increased risk for colon cancer 
(OR = 1.21; 95 % CI = 1.01 – 1.46; Table 3B, Figure 4B), 
indicating a possible synergism between the del1518 del-
allele and the SNP309G-allele.
Similar subgroup analyses of the three remaining cancer 
forms showed no association between del1518 status and risk 
for malignancy at any site (Table 3A–3B, Figure 4A–4B).
DISCUSSION
The findings by Levine’s group [8] and our group 
[18], suggesting that both the MDM2 promoter SNP’s 309 
and 285 may have an effect on cancer risk, implies the 
importance of fine tuning of MDM2 levels with respect 
to carcinogenesis, and also indicate that other MDM2 
promoter variants could potentially be of importance.
Assessments of the promoter P1 del1518 variant 
have previously been performed in a few relatively small 
Chinese cohorts [24, 25, 27–29]. In the present study, we 
determined the distribution of del1518 status in a large 
Caucasian cohort. A major strength of our study is the large 
number of cancer patients and controls compared to other 
studies assessing del1518-status with respect to cancer 
risk. Also, the population based design, using incident 
cancers (breast, lung, colon and prostate) for whom 
DNA samples were collected years prior to diagnosis and 
controls matched by gender, age, and residential area, is a 
strong feature.
In line with previous risk assessments in Chinese 
populations [24, 25, 28], we found no association between 
del1518 status and risk for cancer of the breast, lung or 
prostate. We did, however, observe a positive association 
with colon cancer risk. Somewhat surprisingly, we 
Figure 3: del1518 polymorphism and cancer risk. Forest plot illustrating the effect of the MDM2 del1518 polymorphism on the 
risk of breast-, colon-, lung- and prostate cancer, applying the dominant model (comparison of del1518 del/del + del/ins genotypes versus 
the ins/ins genotype).
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Healthy Controls 155 (10.6) 623 (42.6) 686 (46.9) 1.00 - 1.00
 Women 70 (12.3) 311 (41.1) 359 (46.6) 1.00 - 1.00
 Men 85 (10.2) 312 (42.9) 327 (46.9) 1.00 - 1.00
Colon cancer 71 (11.3) 283 (44.9) 277 (43.9) 0.93 (0.69-1.26) 0.646 0.89 (0.74-1.07) 0.958
 Women 34 (10.6) 140 (43.5) 148 (46.0) 0.89 (0.57-1.36) 0.576 0.90 (0.69-1.17) 0.463
 Men 37 (12.0) 142 (46.3) 129 (4.8) 0.98 (0.65-1.48) 0.916 0.87 (0.67-1.14) 0.338
Lung cancer 63 (11.1) 245 (43.2) 259 (45.7) 0.95 (0.70-1.29) 0.749 0.95 (0.79-1.16) 0.655
 Women 23 (10.1) 110 (48.3) 95 (41.7) 0.93 (0.57-1.53) 0.797 0.76 (0.56-1.02) 0.081
 Men 40 (11.8) 135 (39.8) 164 (48.4) 0.99 (0.67-1.48) 1.000 1.14 (0.88-1.47) 0.355
Breast cancerc 66 (9.8) 279 (41.5) 327 (48.7) 1.00 (0.67-1.37) 0.857 1.01 (0.82-1.24) 0.958
Prostate cancerd 108 (10.9) 456 (46.2) 424 (42.9) 1.08 (0.80-1.47) 0.643 0.91 (0.75-1.11) 0.375
adel/del + ins/del versus ins/ins
bdel/del versus ins/del + ins/ins
ccompared to female controls only
dcompared to male controls only







ins/ins ins/del del/dela Ins/del vs. ins/ins
Healthy Controls 628 (35.2) 1154 (64.8) - 1.00 -
 Women 312 (35.5) 566 (64.5)
 Men 316 (35.0) 588 (65.0)
Colon cancer 221 (31.0) 492 (69.0) - 1.21 (1.01-1.46) 0.044
 Women 109 (30.1) 253 (69.9) 1.28 (0.98-1.67) 0.075
 Men 112 (31.9) 239 (68.1) 1.15 (0.88-1.49) 0.320
Lung cancer 201 (34.7) 379 (65.3) - 1.03 (0.84-1.25) 0.841
 Women 66 (32.5) 137 (67.5) 1.14 (0.83-1.58) 0.462
 Men 135 (35.8) 242 (64.2) 0.96 (0.75-1.24) 0.797
Breast cancerb 264 (33.3) 530 (66.8) - 1.11 (0.90-1.36) 0.328
Prostate cancerc 386 (33.1) 782 (67.0) - 1.10 (0.94-1.29) 0.234
ano observations since del1518 del is linked to SNP309T
bcompared to female controls only
ccompared to male controls only
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found an effect on colon cancer among individuals 
heterozygous, but not homozygous, for del1518. However, 
as the del1518 variant is linked to the SNP309T allele, 
homozygosity for del1518 is restricted to individuals 
harboring the SNP309TT genotype. Additionally, after 
stratifying our data according to SNP309 status, we 
found heterozygousity for the del1518 del allele to be 
associated with an increased risk of colon cancer among 
individuals carrying the SNP309TG genotype, but not 
among SNP309TT homozygous individuals. Although the 
statistical significance was borderline, this may indicate a 
synergistic effect of these two polymorphisms. Notably, 
Figure 4: Impact of the del1518 polymorphism on cancer risk among SNP309. Forest plots illustrating the effect of the MDM2 
del1518 polymorphism on the risk of breast-, colon-, lung- and prostate cancer, applying the dominant model (comparison of del1518 del/
del + del/ins genotypes versus the ins/ins genotype) among individuals carrying the SNP309TT genotype A. and (del1518 del/ins versus 
ins/ins) among individuals harboring the SNP309TG genotype B. (Due to the strong linkage between the del1518 del-allele and the 
SNP309T-allele, the group of homozygous del/del was non-evaluable within individuals with the SNP309TG-genotype).
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studies on other genes have revealed that individuals 
harboring heterozygous mutations may be at risk of 
different diseases compared to homozygous carriers [32, 
33]. Such effects may potentially differ between cancer 
forms as well; previously, we reported that the SNP285C 
allele significantly reduces the risk for breast cancer 
among SNP309GG homozygous individuals, whereas in 
ovarian cancer, the effect of SNP285C was significant 
among SNP309TG individuals only [20, 18]. Here, 
the possibility exists that del1518 may be detrimental 
in concert with SNP309G heterozygosity (individuals 
harboring the SNP309TG genotype), but not exert a 
similar effect among SNP309TT carriers.
Left sided and right sided colon cancers are known 
to be different with respect to histological and molecular 
characteristics [34], and also the genetic mechanisms 
initiating the tumorigenic process have been found to 
be dissimilar [35]. There are evidence that hereditary 
nonpolyposis colon cancer (HNPCC) in general are 
found in right sided colon cancer [36], while familial 
adenomatous polyposis (FAP) dominates in left sided 
colon cancer [37]. However, although we only observed 
an increased OR among individuals suffering from left 
sided colon cancer, a clear trend for increased risk was 
observed also among patients harboring right sided colon 
cancer. The lack of statistical significance in this group 
may be a result of limited statistical power. Thus, whether 
the del1518 polymorphism is associated with increased 
risk for both left sided – and right sided colon cancer may 
need to be explored in independent populations.
Previously, we showed that MDM2 SNP285 is part 
of a predicted estrogen response element (ERE), where 
both Sp1 and ERα may bind and affect tumorigenesis 
[21]. However, when assessing SNP285 and cancer risk 
among “gender neutral” cancer forms (i.e., lung and colon 
cancer), we observed only moderate gender differences 
[20]. In the present study, corresponding to our previous 
findings regarding SNP285, we found no gender specific 
effect of del1518 on cancer risk in either cancer form. Taken 
together, these data indicate that the effect on cancer risk of 
the germline variations in the MDM2 promoter regions, in 
general, are more dependent on tissue type than on gender.
In conclusion, we find an association of del1518 
with the risk of colorectal cancer and no association for 
cancer of the prostate, breast or lung. The finding for colon 
cancer, however, warrants confirmation by others.
MATERIALS AND METHODS
Study populations
To assess potential impact of del1518 status on 
cancer risk, we genotyped this variant in blood DNA from 
10,830 individuals drawn from the Norwegian population-
based Cohort of Norway (CONOR) study [31], previously 
described in [20]. This sample set included 3,749 cancer-
free controls as well as incident cases of four major cancer 
forms: cancer of the breast (n=1,717), prostate (n=2,501), 
lung (n=1,331) and colon (n=1,532).
The African-American cohort (n=300) was from the 
Laboratory of Human Carcinogenesis, Center for Cancer 
Research, National Cancer Institute Bethesda, USA. 
These samples were collected as part of an ongoing case 
control study with previously described inclusion criteria 
[38]. Briefly, population controls were identified from the 
Department of Motor Vehicles, MD, USA and frequency 
matched to cases by age and gender. Written informed 
consent was obtained from all participants, and the study 
was approved by the Institutional Review Boards of the 
participating institutions.
In silico predictions
Potential novel binding sites for transcription 
factors, generated by the deletion variant of the MDM2 
del1518 polymorphism, were predicted using the JASPAR 
database [30] (http://jaspardev.genereg.net). Predictions 
were made using the default settings of the database (cut 
off threshold of 80%).
MDM2 del1518 genotyping
All samples were genotyped for MDM2 del1518 by 
using DNA extracted from peripheral white blood cells. The 
region of the MDM2 promoter P1 containing the del1518 
was amplified by PCR using the VWR Taq DNA Polymerase 
system (VWR), with a primer pair previously described 
[27]. The amplification was performed in a total reaction 
volume of 25 µl, containing 2.5 µl 10x Key Buffer, 0.2 mM 
dNTPs, 0.2 µM each primer, 1.25 U Taq polymerase and 1 µl 
template DNA (10-100 µg). The thermo-cycling conditions 
were an initial step of 94 °C for 5 min, 35 cycles of 94 °C for 
30 sec, 58 °C for 30 sec and 72 °C for 30 sec, followed by a 
final elongation step of 72 °C for 10 min. The PCR products 
were separated by electrophoresis in a 3% agarose gel and 
visualized by GelRedTM Nucleic Acid Gel Stain (BIOTIUM). 
The del1518 insertion and deletion alleles were observed as 
481 bps – and 441 bps bands respectively.
All samples were previously genotyped for MDM2 
SNP285 and SNP309 status [20] using custom LightSNiP 
assays (TIB MOLBIOL Syntheselabor GmbH, Berlin, 
Germany) as described in detail elsewhere [39].
Statistical analysis
Potential deviations from Hardy-Weinberg 
equilibrium in cancer patients as well as healthy controls 
were evaluated using the Chi-square test. Possible 
associations between MDM2 del1518 and cancer risk, both 
in total and in stratified groups, were estimated by Odds 
Ratios (OR) and Fisher exact tests. ORs are given with 
95% confidence intervals (CI) and p-values from Fisher 
exact tests are given as two-sided and cumulative.
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All statistical analyses were performed using the 
IBM SPSS statistics (version 19) software package.
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